RISK ADJUSTMENT AND REFERENCE POINTS
DESIGN AND VALIDATION OF A NEW WEB-BASED STANDARD GAMBLE INTERVIEW
HOW STABLE ARE SOCIAL PREFERENCE WEIGHTS FOR EQ-5D
DEVELOPING A PREFERENCE-BASED MEASURE FOR POSTMENOPAUSAL HEALTH
ACARBOSE FOR THE PREVENTION OF TYPE II DIABETES IN CANADA
PIOGLITAZONE MONOTHERAPY IS ASSOCIATED WITH A SIGNIFICANTLY LOWER INCIDENCE OF CARDIOVASCULAR EVENTS THAN IS INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES
COST-EFFECTIVENESS OF ROSIGLITAZONE-METFORMIN COMBINATION IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES IN GERMANY
TYPE OF DIABETES AND ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG)
A PROBLEM SHARED IS A PROBLEM HALVED? COST ACCEPTABILITY OF SHARED CARE VS HOSPITAL TREATMENT
THE IMPACT OF TREATMENT MANAGEMENT ALGORITHMS AND EVALUATED TIME HORIZON ON ANTIVIRAL TREATMENT COSTS IN CHRONIC HEPATITIS C
END STAGE RENAL DISEASE IN FRANCE
CHILDHOOD VACCINATION AGAINST VARICELLA IN FRANCE
A TALE OF TWO STUDIES
THE PARAMETRIC BOOTSTRAP
THE IMPLICATIONS OF COMBINING HETEROGENEOUS PATIENT POPULATIONS IN META-ANALYSES
STOCHASTIC ANALYSIS OF AN RANDOMIZED CONTROLLED TRIAL IN REHABILITATION OF LOW BACK PATIENTS
ASTHMA TREATMENT PREFERENCE STUDY— A CONJOINT ANALYSIS OF PREFERRED DRUG TREATMENTS
TRANSFORMING THE UNIFIED PARKINSON'S DISEASE RATING SCALE INTO A UTILITY SCALE
WILLINGNESS TO PAY FOR HEARING AIDS IN THE NETHERLANDS
CLINICAL INCONTINENCE SCORE RELATES TO HEALTH UTILITY VALUES
COST-UTILITY ANALYSIS OF “ON DEMAND” RABEPRAZOLE AND ESOMEPRAZOLE FOR SYMPTOMATIC GASTRO OESOPHAGEAL REFLUX DISEASE
A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC, INJECTABLE TREATMENT AND EXISTING INTERVENTIONS IN GASTRO-OESOPHAGEAL REFLUX DISEASE
COSTS OF GASTROENTERITIS IN THE NETHERLANDS
POTENTIAL HOSPITAL SAVINGS RELATED TO THE ADMINISTRATION OF ESOMEPRAZOLE TABLETS THROUGH GASTRIC TUBES IN PATIENTS CURRENTLY TREATED WITH INJECTABLE PPIS
A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION
THE ECONOMIC BURDEN OF STROKE IN SPAIN
PROSPECTIVE COHORT STUDY IN HIP FRACTURE
IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION,AND MICROALBUMINURIA
ASSESSING GENERALISABILITY OF COST-EFFECTIVENESS ESTIMATES IN MULTINATIONAL STUDIES
A USER-FRIENDLY TOOL FOR EVALUATING AND IMPROVING THE TRANSFERABILITY OF ECONOMIC EVALUATION RESULTS BETWEEN COUNTRIES
ESTIMATING COST-EFFECTIVENESS IN THE ABSENCE OF HEAD-TO-HEAD CLINICAL TRIALS—EXAMPLES OF TWO RECENT TECHNOLOGY ASSESSMENTS FOR NICE
HOW FREQUENTLYARE ECONOMIC EVALUATIONS USED IN DECISION MAKING?
HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN AN EVIDENCE-BASED ASTHMA DISEASE MANAGEMENT PROGRAM
OUALITY OF LIFE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY
ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE
A RANDOMIZED TRIAL OF MEDICAL CO-PRESCRIPTION OF HEROIN TO CHRONIC, TREATMENT-RESISTANT HEROIN ADDICTS IN THE NETHERLANDS
COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPY, COGNITIVE BEHAVIOUR THERAPY AND THEIR COMBINATION FOR PEOPLE WITH BULIMIA NERVOSA IN THE UK
COST-EFFECTIVENESS OF THE HIT PROGRAMME IN PATIENTS WITH SCHIZOPHRENIA AND PERSISTENT AUDITORY HALLUCINATIONS
HOSPITALIZATION RELATED TO ABUSE OF THE ELDERLY WITH DEMENTIA AND OTHER MENTAL HEALTH DISORDERS
CHILDREN WITH ADHD (ATTENTION-DEFICIT/HYPERACTIVITY DISORDER)
SHORT AND LONG TERM COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST- SEGMENT ELEVATION (ACS) IN SCANDINAVIAN COUNTRIES
AN ECONOMIC EVALUATION OF CLOPIDOGREL VS.ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISK ATHEROTHROMBOTIC PATIENTS
COST-EFFECTIVENESS OF A NEW ANTITHROMBOTIC AGENT
CLINICAL OUTCOMES AND COSTS OF DRUG ELUTING STENTS IN THE CARDIAC CATHERIZATION LAB
LOWER PERSISTENCE WITH ANTIHYPERTENSIVE DRUGS AMONG WOMEN COMPARED TO MEN
DETERMINANTS OF NON ADHERENCE TO ANTIHYPERTENSIVE DRUG TREATMENT
DISCONTINUATION RATES OF PHARMACOLOGICAL TREATMENTS FOR OVERACTIVE BLADDER
LONG-TERM PERSISTENCE WITH STATIN THERAPY IN DAILY MEDICAL PRACTICE
COST-EFFECTIVENESS MODEL OF RECOMBINANT HUMAN CHORIONIC GONADOTROPIN (R-HCG) VERSUS URINARY HCG (U-HCG) FOR ASSISTED REPRODUCTIVE TECHNIQUES (ART) IN THE USA
HEALTH ECONOMIC ASSESSMENT OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
INTEGRATED ECONOMIC EVALUATION OF ENFUVIRTIDE (ENF) IN THE US USING A COMBINATION OF COST-EFFECTIVENES ANALYSIS (CEA) AND BUDGET IMPACT ANALYSIS (BIA) TO ENHANCE HEALTH CARE DECISION-MAKING
COST-EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH ADVANCED AND/OR METASTATIC BREAST CANCER IN FRANCE
RESPONSIVENESS TO CHANGE OF THE SHORT FORM (SF)-12 HEALTH STATUS INSTRUMENT IN PATIENTS WITH CEREBROVASCULAR DISEASE
PERFORMANCE OF THE EQ-5D IN PATIENTS WITH IRRITABLE BOWEL SYNDROME
PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME IN FRANCE—INSTANT STUDY
WITHDRAWN
A MARKOV MODELLED PHARMACOECONOMIC ANALYSIS OF BIMATOPROST 0.03% (LUMIGAN®) IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION AS AN ALTERNATIVE TO FILTRATION SURGERY IN ITALY
BURDEN OF ILLNESS OF INFLUENZA
INITIAL INSERTION OF A METAL STENT FOR PALLIATION OF MALIGNANT BILIARY OBSTRUCTION
COST-BENEFIT ANALYSIS OF AN INTERNET-BASED PATIENT EDUCATION PROGRAMME FOR ASTHMATIC CHILDREN AND ADOLESCENTS
A HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI
COST-EFFECTIVENESS OF LOVASTATIN, CHOLESTYRAMINE AND GEMFIBROZIL FOR THE PRIMARY PREVENTION OF CORONARY HEART DISEASE THROUGH CHOLESTEROL REDUCTION IN CATALONIA, SPAIN
CONTROLRISC STUDY
A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION
PRESCRIPTION DRUG INFORMATION
CHARACTERIZATION OF POLYPHARMACY ISSUES AND SUBSEQUENT INTERVENTION IN A POPULATION OF ELDERLY COMMUNITY-DWELLING INDIVIDUALS
THE ANTIBIOTIC USE IN POLAND IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADOLESCENTS AND ADULTS VERSUS CURRENT GUIDELINES
PATTERNS OF USE OF COXIBS AND NON-SELECTIVE NSAIDS IN THE ELDERLY POPULATION OF QUEBEC (CANADA)
FINANCING PHARMACEUTICAL R&D
LISTENING TO OUR CONSUMERS
A DEMONSTRATION OF THE USE OF BAYESIAN DECISION THEORY TO OPTIMISE DRUG DEVELOPMENT PROGRAMMES
THE IMPACT OF HEALTH CARE ATTITUDES ON PATIENT REPORTED OUTCOMES (PRO'S)
CHRONIC ALLERGIC RHINITIS, ECONOMICS IMPACT
THE BURDEN OF ALLERGIC CONJUNCTIVITIS IN THE UK
RESEARCH 5771
CONSTRUCT VALIDITY AND RELIABILITY OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ)
PREVALENCE OF LOW VISION AND BLINDNESS IN FRANCE
PREVALENCE AND BURDEN OF BLINDNESS AND LOW VISION IN SUBJECTS LIVING IN INSTITUTIONS
RESEARCH 5134
VISION IMPAIRMENT AS AN INDEPENDENT RISK FACTOR OF INSTITUTIONALIZATION
SCORING OF VISUAL FIELD MEASURED THROUGH HUMPHREY PERIMETRY
COST AND EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF GLAUCOMA
COMPARISON OF THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF LUMIGAN AND XALATAN IN THE TREATMENT OF GLAUCOMA
ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6 EUROPEAN COUNTRIES
TREATMENT DURATION AS A COST DRIVER OF GLAUCOMA CARE
COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES
COST-EFFECTIVENESS ANALYSIS OF PMMA, SILICONE, AND ACRYLIC INTRA-OCULAR LENSES IN CATARACT THERAPY IN FOUR EUROPEAN COUNTRIES
A MULTI-CENTER RETROSPECTIVE STUDY OF RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH GLAUCOMA MANAGEMENT IN FRANCE AND SWEDEN
PSYCHOMETRIC VALIDATION OF THE NEI-VFQ 25 FRENCH VERSION IN A POPULATION OF PATIENTS TREATED FOR OCULAR HYPERTENSION AND GLAUCOMA
ASSESSING THE VALUE OF LASER IN SITU KERATOMILEUSIS (LASIK) BY PATIENT REPORTED OUTCOMES
IMPROVEMENT IN VISION TARGETED QUALITY OF LIFE (QOL) AFTER CATARACT SURGERY WITH IMPLANTATION OF ACRYSOF® NATURAL INTRAOCULAR LENS (IOL)
PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION, ELEVATED TROPONIN T LEVELS AND DIABETES MELLITUS. OUTCOME AT THREE MONTHS
NEW TECHNOLOGIES IN THE US MEDICARE
EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE
PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN ASIAN PATIENTS
OUTCOME AND PROGNOSTIC VALUE OF TROPONIN T IN PATIENTS WITH UNSTABLE ANGINA OR NON-Q-WAVE MYOCARDIAL INFARCTION
ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN ESSENTIAL HYPERTENSION IN SLOVAK REPUBLIC
MITRAL REPAIR CAN BE SAFELY PERFORMED IN CASES OF INCREASED COMPLEXITY
CHOICE OF FIRST-LINE TREATMENT FOR HYPERTENSION IN THE UK
THE USE OF SHORT MESSAGES TO THE PATIENT'S MOBILE PHONE AS HEALTH CARE TOOL IN HYPERTENSION
IMPROVED COMPLIANCE AND PERSISTENCE WITH ATORVASTATINE THROUGH A PHARMACY-BASED INTERVENTION
PREDICTIVE VALUE OF TROPONIN T LEVELS FOR HEART FAILURE AFTER UNSTABLE ANGINA OR NON ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
EFFECT OF EPROSARTAN ON PULSE PRESSURE PREDICTIVE FACTORS OF RESPONSE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES COMPARING READMISSION RATES AND MORTALITY IN PATIENTS WITH HEART FAILURE
EFFECTIVENESS OF SELF-MEASUREMENT OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS. DIOAMPA STUDY
LOW GOAL ATTAINMENT IN COMMON DAILY PRACTICE AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE NETHERLANDS
EFFECTIVENESS AND COST-EFFECTIVENESS OF THE AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN THE DIAGNOSTIC OF HYPERTENSION
COST-EFFECTIVENESS ANALYSIS OF DALTEPARIN IN PROLONGED PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS AFTER HIP ARTHROPLASTY
HEALTH SYSTEM COSTS OF OUT-OF-HOSPITAL CARDIAC ARREST IN RELATION TO TIME TO SHOCK
A PROBABILISTIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF A NEW STATIN (ROSUVASTATIN) IN THE UK
ECONOMIC MODELLING OF ANTIPLATELET THERAPY IN THE PREVENTION OF RECURRENT STROKE
THE COST OF STROKE IN SWEDEN—AN INCIDENCE ESTIMATE
ECONOMIC EVALUATION OF FONDAPARINUX COMPARED TO ENOXAPARIN IN VENOUS THROMBOEMBOLISM PREVENTION FOLLOWING HIP FRACTURE SURGERY
ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
THE MAHLER STUDY
THE COST AND THE MANAGEMENT OF THE ACUTE PHASE OF MYOCARDIAL INFARCTION AND STROKE IN HUNGARY
COST-EFFECTIVENESS OF EXTENDING PROPHYLAXIS WITH FONDAPARINUX IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY
COST-EFFECTIVENESS ANALYSIS OF ANTITHROMBOTIC TREATMENT WITH CLOPIDOGREL IN PATIENTS WITH MYOCARDIAL INFARCTION, STROKE, AND PERIPHERAL ARTERIAL DISEASE IN THE NETHERLANDS
ECONOMIC EVALUATION AND SURVIVAL ANALYSIS OF IMMUNO-ADSORPTION IN PATIENTS WITH DILATED CARDIOMYOPATHY
USE OF RESOURCES AND COST IMPLICATIONS OF STROKE PROPHYLAXIS WITH WARFARIN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN GREEK PATIENTS WITH HYPERLIPIDAEMIA
ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS IN HUNGARY
COSTS OF HOSPITALIZATION IN DEPARTMENT OF CARDIOLOGY FOR PATIENTS WITH SYSTOLIC HEART FAILURE IN FRANCE
THE COST-EFFECTIVENESS OF TARKA IN THE TREATMENT OF HEART FAILURE AFTER MYOCARDIAL INFARCTION IN THE US HEALTH CARE SETTING
COST-EFFECTIVENESS OF FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA
BURDEN OF HYPERCHOLESTEROLEMIA IN GERMANY
COST-EFFECTIVENESS OF EARLY THROMBOLYSIS FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
THE ADDITIONAL TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH METOPROLOL CR/XL WILL LEAD TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM
COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS
ECONOMIC EVALUATION OF THE MEDENOX (PROPHYLAXIS IN MEDICAL PATIENTS WITH ENOXAPARIN) TRIAL FROM THE PERSPECTIVE OF HOSPITALS IN GERMANY
ASSESSMENT OF THE COST OF CARDIOVASCULAR DEATH
A COST ANALYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES USING CLOPIDOGREL IN ADDITION TO ASPIRIN IN A HONG KONG PUBLIC HOSPITAL
ECONOMIC ANALYSIS OF THE USE OF CONTRAST MEDIA DURING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE AND SPAIN
AN EVALUATION OF THE COSTS ASSOCIATED WITH ACUTE MI TREATMENT IN AND OUT OF HOSPITALS IN GREECE
PHARMACOECONOMIC EVALUATION OF VASOTEC® IN HYPERTENSIVE PATIENTS WITH CONGESTIVE HEART FAILURE
LONG-TERM COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY COMPARED TO FIBRINOLYSIS IN ACUTE MYOCARDIAL INFARCTION
SWITCHING PATIENTS TO ROSUVASTATIN FROM ATORVASTATIN OR OTHER STATINS IS COST-EFFECTIVE
A COST-EFFECTIVENESS ANALYSIS OF TAXUS™ DRUG-ELUTING STENT IN THE UK
LONG-TERM COST-EFFECTIVENESS OF INVASIVE STRATEGY IN PATIENT WITH UNSTABLE CORONARY ARTERY DISEASE RESULTS FROM THE FRISC-II TRIAL
COST-EFFECTIVENESS ANALYSIS OF CITICOLINE VS CONVENTIONAL TREATMENT IN STROKE PATIENTS
COSTS OF THE DIAGNOSIS OF RENAL ARTERY STENOSIS
IRBESARTAN IS COST-SAVING COMPARED TO AMLODIPINE AND STANDARD BLOOD PRESSURE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN HUNGARY
ECONOMIC ANALYSIS OF THE USE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION (ACS) FROM THE RUSSIAN HEALTH CARE SYSTEM PERSPECTIVE
MANAGEMENT OF THE PRIMARY CARE HYPERCHOLESTEROLEMIC PATIENTS THROUGH A CLINICAL DECISION SUPPORT SYSTEM. OPTIMCARE STUDY REPORT
ECONOMIC EVALUATION OF ROSUVASTATIN IN A NATURALISTIC SETTING
“FAST-TRACKING” IN THE CARDIAC INTENSIVE CARE UNIT
ESTABLISHING THE COST-EFFECTIVENESS OF STATINS IN THE PRIMARY PREVENTION OF CHD USING A QUASI MARKOV MODEL
COST EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY IN DIABETIC PATIENTS IN ITALY
ECONOMIC IMPACT OF SELECTED FIXED-COMBINATION ANGIOTENSIN-CONVERTING ENZYME INHIBITOR/CALCIUM CHANNEL BLOCKER ANTI-HYPERTENSIVES AMONG PATIENTS WITH DIABETES
ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY
INTRODUCTION OF ROSUVASTATIN WILL ENABLE MORE PATIENTS TO ACHIEVE GUIDELINE LDL-C GOALS WITHIN A FIXED BUDGET IN THE UK
THE COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH ENOXAPARIN VERSUS SHORT-TERM PROPHYLAXIS AFTER ELECTIVE HIP REPLACEMENT IN POLAND
CLINICAL AND ECONOMIC OUTCOMES OF FONDAPARINUX VS. ENOXAPARIN IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY IN SPAIN
COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN THE NETHERLANDS
COST-EFFECTIVENESS ANALYSIS OF CORONARY REVASCULARISATION TECHNIQUES AVAILABLE FOR THE TREATMENT OF ISCHAEMIC HEART DISEASE
EVALUATING THE ECONOMIC VALUE OF SIROLIMUS-ELUTING STENT IN KOREA
ONE BILLION EURO FOR THE TREATMENT WITH CSE-ANTAGONISTS IN GERMANY— WHAT ARE THE RESULTS?
AN ECONOMIC EVALUATION OF ALTEPLASE, RETEPLASE AND TENECTEPLASE IN TREATMENT OF ACUTE MI IN GREECE
A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS OF STATINS IN CARDIOVASCULAR RISK MANAGEMENT
THE COST-EFFECTIVENESS OF CYP2C9 GENOTYPING IN MANAGEMENT OF WARFARIN THERAPY—A DECISION TREE ANAYSIS
A PHARMACOECONOMIC COMPARISON OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN USAGE IN ACUTE CORONARY SYNDROME IN RUSSIA
AN ECONOMIC EVALUATION OF TREATMENTS FOR ACUTE MI IN GREECE IN ELDERLY AND LATE TREATMENT PATIENTS
COST-EFFECTIVENESS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE NETHERLANDS
DEVELOPMENT OF PATIENT-REPORTED OUTCOME MEASURES FOR PULMONARY ARTERIAL HYPERTENSION
MEASURING HEALTH RELATED QUALITY OF LIFE AFTER STROKE
PROJECTED LIFE YEAR GAINED AND OTHER BENEFITS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT ATTAINING TOTAL CHOLESTEROL GOAL WITH STATIN MONOTHERAPY IN FINLAND
IS THE MLHF QUESTIONNAIRE VALID FOR INTERNATIONAL MULTICENTRIC STUDIES?
THE ECONOMIC ASSESSMENT OF LIPID LOWERING THERAPY WITH EZETIMIBE IN SPAIN
QUALITY OF LIFE IN CHRONIC PATHOLOGIES IN PRIMARY CARE
DEVELOPMENT AND VALIDATION OF THE NEW HEALTH-RELATED QUALITY OF LIFE INSTRUMENT SPECIFIC TO PATIENTS WITH CORONARY ARTERY DISEASE (CAD) IN POLAND
EARLY EVOLUTION, DETERMINANTS AND PREDICTIVE POWER OF HEALTH RELATED QUALITY OF LIFE IN A MULTICENTRIC POPULATION OF PATIENTS WITH HEART FAILURE
IMPROVED GLYCAEMIC CONTROL AND LESS HYPOGLYCAEMIA WITH INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES LEADS TO FEWER LONG-TERM COMPLICATIONS—RESULTS OF THE DIABETES MELLITUS SIMULATION MODEL
IS THERE A GAIN WITH THE PAIN? ASSESSMENT OF THE RELATIONSHIP BETWEEN SELF-REPORTED ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) AND HBA1C LEVELS AMONG TYPE 2 DIABETICS
CLAIMS DATA MEASUREMENTS OF MEDICATION ADHERENCE AND METABOLIC OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES (DM2)
POPULATION-BASED DIABETES INTERVENTION IN A MANAGED CARE SETTING
EVIDENCE-BASED ASSESSMENT OF PATIENTS' RISK AND POTENTIAL REGARDING THE LONG-TERM COMPLICATIONS OF DIABETES USING A NEW MODEL OF PROGNOSIS IN THE DM PROJECT DIAMART
PREVALENCE OF RENAL FAILURE IN DIABETES TYPE 2
THE IMPACT ON GLYCEMIC CONTROL OF DIABETIC PATIENTS BY A HOSPITAL PHARMACIST-MANAGED COMPLICANCE CLINIC IN HONG KONG
AN ANALYSIS OF THE RELATIONSHIP BETWEEN RAPID TRANSITION TO INSULIN, AREA UNDER THE CURVE FOR HBA1C MEASURES ACROSS TIME AND DIABETES-RELATED COMPLICATIONS
THE COMPACT-STUDY
DIABETES DISEASE MANAGEMENT IS ASSOCIATED WITH PHARMACY SAVINGS IN A MANAGED CARE SETTING
THE ECONOMIC CONSEQUENCES OF DIABETES TYPE 2 IN POLAND
TYPE-2 DIABETES AND HISPITAL COSTS ACCORDING TO OBESITY
PREDICTORS OF EMERGENCY DEPARTMENT VISITS IN ELDERLY PATIENTS WITH DIABETES
COST-EFFECTIVENESS ANALYSIS OF THE ACARBOSE PHARMACOLOGICAL TREATMENT AS A PREVENTIVE MEASURE OF THE DEVELOPMENT OF TYPE 2 DIABETES IN SUBJECTS DIAGNOSED OF IMPAIRED GLUCOSE TOLERANCE (IGT)
RISK OF CONGESTIVE HEART FAILURE IN TYPE 2 DIABETICS EXPOSED TO PIOGLITAZONE VS INSULIN
COST-EFFECTIVENESS OF BLOOD PRESSURE AND URINARY ALBUMIN CONTROL IN DIABETICS WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER
PREDICTED COSTS AND OUTCOMES FROM REDUCED VIBRATION DETECTION IN PEOPLE WITH DIABETES IN THE UK
THE COMPLICATIONS IMPACT ON DIABETES TYPE 2 DIRECT COSTS IN POLAND
ADVANCED TOOLS FOR ALLOCATION OF MEDICAL PRODUCTS
A COST-UTILITY ANALYSIS OF INSULIN GLARGINE (LANTUS®) IN THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES
THE IMPACT OF DIABETES TYPE 2 ON QUALITY OF LIFE
AN EVIDENCE-BASED APPROACH PROVIDES A QUANTITATIVE ASSESSMENT OF THE EFFICACY OF ESOMEPRAZOLE FOR HEALING OF EROSIVE ESOPHAGITIS BASED ON DISEASE SEVERITY
A RETROSPECTIVE AUDIT OF PATIENTS REDUCING PROTON PUMP INHIBITOR DOSE TO LANSOPRAZOLE 15MG
META-ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI
ESOMEPRAZOLE AS MAINTENANCE THERAPY IN EROSIVE ESOPHAGITIS
ECONOMIC BURDEN OF IRRITABLE BOWEL SYNDROME (IBS)
COST EFFECTIVENESS OF CONTINUOUS AND ON-DEMAND THERAPY WITH ESOMEPRAZOLE 20MG IN PATIENTS WITH SYMPTOMATIC GASTROESOPHGEAL REFLUX DISEASE (GERD)
COST ANALYSIS OF A NEW PROPOSAL FOR REIMBURSEMENT OF PROTON PUMP INHIBITOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN BELGIUM
COST-MINIMISATION ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI
A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC INJECTABLE TREATMENT VERSUS SURGERY IN PATIENTS WITH SEVERE GASTRO ESOPHAGEAL REFLUX DISEASE IN FRANCE
COST OF ILLNESS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN ITALY
COST OF ILLNESS AND QUALITY OF LIFE OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN ITALY
USING A COST-UTILITY ANALYSIS FOR ASSESSING SENSITIVITY IN DRUG PRICES OF ESOMEPRAZOLE VERSUS OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX OESOPHAGITIS IN THE UK
IMPACT ON WORK PRODUCTIVITY OF UPPER GASTROINTESTINAL SYMPTOMS ASSOCIATED WITH CHRONIC NSAID THERAPY IN A SWEDISH STUDY POPULATION
METHYLPHENIDATE FORMULATION IS ASSOCIATED WITH ACCIDENT/INJURY RATE IN CHILDREN WITH ADHD
EVALUATION OF ANTIDEPRESSANT MEDICATION ADHERENCE IN A NOT FOR PROFIT HEALTH CARE ORGANIZATION
EVALUATION OF MEDICAL DIAGNOSES FOR TEXAS MEDICAID PATIENTS PRESCRIBED ATYPICAL ANTIPSYCHOTIC MEDICATIONS
2-YEAR OUTCOMES OF RISPERDAL® CONSTA™—THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC
FUNCTIONING AND HEALTH CARE RESOURCE USE OF SCHIZOPHRENIC PATIENTS IN A ONE-YEAR FOLLOW-UP STUDY. SOHO STUDY
PHARMACOUTILIZATION OF ANTIDEPRESSANT DRUGS IN PRIMARY CARE
COST EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT VERSUS CARE AS USUAL FOR PANIC DISORDER AND/OR DEPRESSION DRIVEN CHEST PAIN
PREVALENCE AND MEDICAL CARE COSTS OF ANXIETY DISORDERS IN THE UNITED STATES
THE SOCIO-ECONOMIC BURDEN OF BIPOLAR DISORDER IN THE NETHERLANDS
COSTS AND EFFECTS OF RISPERDAL CONSTA™ IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN GERMANY
PRODUCTION LOSSES IN BORDERLINE PERSONALITY DISORDER
ECONOMIC CONSEQUENCES OF THE ADVERSE EVENTS RELATED WITH CURRENT ANTIPSYCHOTICS
AFFECTIVE PSYCHOSES IN ADOLESCENTS
THE BURDEN OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN THE NORDIC COUNTRIES—A LITERATURE REVIEW
COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE (LA-RIS) VS HALOPERIDOL DECANOATE AND ORAL OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY
AN ECONOMIC EVALUATION OF ARIPIPRAZOLE VERSUS OLANZAPINE IN A SWEDISH SETTING USING OUTCOMES OF METABOLIC SYNDROME, PROJECTED DIABETES AND CORONARY HEART DISEASE
HEALTH-RELATED QUALITY OF LIFE IN OUTPATIENTS WITH SCHIZOPHRENIA IN SINGAPORE
ZIPRASIDONE VS OLANZAPINE
CLIENT AND STAFF INVOLVEMENT IN FORMAT DESIGN OF A HEALTH-RELATED QUALITY OF LIFE SURVEY FOR INDIVIDUALS WITH SCHIZOPHRENIA, THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEY
TREATMENT WITH PSYCHOSTIMULANTS IS ASSOCIATED WITH DECREASED RATES OF SUBSTANCE ABUSE AND IMPROVED SCHOOL OUTCOMES AMONG CHILDREN WITH AD/HD
PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY
PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY
DEVELOPMENT AND ASSESSMENT OF HEALTH STATE UTILITIES FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN USING PARENT PROXY REPORT
EARLY SUSTAINED REMISSION IN PATIENT-REPORTED OUTCOMES AMONG PRIMARY CARE PATIENTS WITH MAJOR DEPRESSIVE DISORDER
ASSESSING HEALTH-RELATED QUALITY OF LIFE IN CLINICAL TRIALS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER
QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS IN SPAIN
THE USE OF A URINARY CATHETER REMINDER TO REDUCE URINARY CATHETERIZATION IN HOSPITALIZED PATIENTS
TREATMENT PERSISTENCE OF OXYBUTYNIN XL AND TOLTERODINE IR IN A REAL-WORLD CLINICAL PRACTICE SETTING
TREATMENTS RECEIVED FOR STRESS URINARY INCONTINENCE (SUI) SYMPTOMS BY PATIENTS SEEKING HELP WITHIN A UK PRIMARY CARE SETTING
TREATMENT OF URINARY INCONTINENCE IN DAILY PRACTICE DOES NOT COMPLY WITH THE GUIDELINES
COMPARISON OF THE DOSE AND COST OF EPREX BY ROUTE OF ADMINISTRATION
COST-MINIMIZATION ANALYSIS OF TENSION-FREE VAGINAL TAPE VS. OPEN BURCH COLPOSUSPENSION IN FEMALE STRESS URINARY INCONTINENCE
DITROPAN XL VERSUS DETROL IN CANADA
SEVELAMER USE IN HYPERPHOSPHATEMIA
ECONOMICAL IMPACT OF SACRAL NERVE STIMULATION THERAPY IN 62 PATIENTS WITH LOWER URINARY TRACT DYSFUNCTION
A COST ANALYSIS OF ALFUZOSIN IN THE MANAGEMENT OF ACUTE URINARY RETENTION
SURVIVAL IN END-STAGE RENAL DISEASE (ESRD) PATIENTS
COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN KIDNEY TRANSPLANTATION
COMPARISON OF THE PERFORMANCE AND DATA QUALITY OF ELECTRONIC AND PAPER DIARIES FOR BENIGN PROSTATIC HYPERPLASIA (BPH)
“EFFECT SIZE” OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH CHRONIC ALLOGRAFT NEPHROPATHY AND ANEMIA TREATED WITH RH-EPO
VALIDATION STUDY OF THE SPANISH VERSION OF THE ICIQ-SHORT FORM. A USEFUL INSTRUMENT IN DETECTING URINARY INCONTINENCE
LOWER IMPACT ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ELDERLY PATIENS STARTING AND AFTER ONE YEAR OF HEMODIALYSIS (HD) THAN IN YOUNGER PATIENS
EFFECT OF ORAL LOW-DOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1 MG AND NORESTISTERONE ACETATE 0.5 MG) ON CARDIOVASCULAR RISK IN SPANISH POSTMENOPAUSAL WOMEN
EFFECTIVITY AND SAFETY OF ORAL LOW-DOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1 MG AND NORETISTERONE 0.5 MG) IN CLIMACTERIC SYMPTOMS ON SPANISH POSTMENOPAUSAL WOMEN
PULSED OESTROGEN THERAPY WITH INTRANASAL 17-B OESTRADIOL IMPROVES WOMEN'S QUALITY OF LIFE IN THE EARLY POSTMENOPAUSAL PERIOD
VASOMOTOR SYMPTOMS AND QUALITY OF LIFE (QOL) IN POSTMENOPAUSAL WOMEN
QUALITY OF LIFE (QOL) DIFFERENTIATION ANALYSIS IN PATIENTS UNDERGOING CONTROLLED OVARIAN STIMULATION (COS) WITH TWO DIFFERENT PREPARATIONS OF RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE (R-HFSH)
PATIENT AND PARTNER TREATMENT SATISFACTION SCALE (TSS) IN ERECTILE DYSFUNCTION
A NEW INSTRUMENT TO MEASURE THE PSYCHOLOGICAL IMPACT OF ERECTILE DYSFUNCTION. VALIDATION OF A SPANISH VERSION OF THE JOHNSON AND MCCOY'S SELF-CONFIDENCE SCALE
DEVELOPMENT AND INITIAL TESTING OF A NEW PATIENT-REPORTED QUESTIONNAIREERECTION QUALITY SCALE
POTENTIAL FINANCIAL IMPACT OF ITEM RESPONSE THEORY-BASED INDICATIONS FOR LONG-TERM HEALTH CARE FACILITIES
AIDS AND ECONOMIC GROWTH
PERSPECTIVES AND BARRIERS IN THE DEVELOPMENT OF PHARMACOECONOMICS AND ITS APPLICATIONS IN POLAND-PRELIMINARY RESULTS OF A SURVEY
ARE THE RESULTS OF ECONOMIC EVALUATIONS GENERALIZABLE? EVIDENCE FROM STUDIES OF PHARMACEUTICALS IN WESTERN EUROPE
HOW PHARMACOECONOMICS INDICATORS FOR THERAPEUTIC INNOVATIONS IN ACUTE AND CHRONIC DISEASE CAN ASSIST PAYORS IN THE DECISION MAKING PROCESS
RESEARCH 5539
PHARMACOECONOMICS IN HEALTH CARE-DECISION MAKING
THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATION DATABASES (EURO NHEED) PROJECT
THE IMPACT OF CHANGING REIMBURSEMENT MECHANISMS
HOSPITALIZATIONS FOR INJURIES RESULTING FROM CONTACT SPORTS
EFFECT OF COPAY INCREASE ON COMPLIANCE
3THE ECONOMIC IMPLICATIONS OF NON-COMPLIANCE AFTER RENAL TRANSPLANTATION
POLICIES FOR INCLUSION OF DRUGS FOR REIMBURSEMENT BY THE PHILIPPINE HEALTH INSURANCE CORPORATION
DRUG PRICE INDICES 1980–2002 IN FINLAND
COMPARISON OF MARKET EXCLUSIVITY OF PHARMACEUTICALS IN CANADA, THE UNITED STATES, THE UNITED KINGDOM AND FRANCE
SPANISH NATIONAL HEALTH SERVICE
SURVEY ON DRUG VALUE ASSESSMENT AMONG PRESCRIBERS AND PAYERS IN ITALIAN HOSPITALS
REIMBURSING OFFICE-BASED DRUG MANAGEMENT COSTS
CONSUMER VALUATION OF PRESCRIPTION DRUG BENEFIT PLANS
MARKET SHARE AND CHARACTERISTICS OF GENERIC DRUGS IN GREECE
IMPACT OF PHARMACY INTERVENTIONS ON QUALITY OF HOSPITAL PRESCRIBING
AN INVESTIGATION OF GENERIC DRUG UTILISATION AND POTENTIAL SAVINGS FROM GENERIC SUBSTITUTION IN THE IRISH HEALTH CARE SETTING
THE DRUG PRICE REFERENCE INDEX STUDY OF THE PHILIPPINE HEALTH INSURANCE CORPORATION
THE VALUE OF BOARD OF PHARMACEUTICAL SPECIALTY CERTIFICATION
MECHANISMS AND OUTCOMES OF UTILIZATION REVIEW CONDUCTED AMONG PHIC-ACCREDITED HEALTH CARE FACILITIES IN THE PHILIPPINES
INTENSIVIST PRACTICE CHANGE IN GLUCOSE CONTROL FOR CRITICALLY ILL PATIENTS
THE ASSOCIATION OF RECOMMENDED SURGICAL SITE INFECTION GUIDELINES AND OTHER FACTORS WITH HOSPITAL LENGTH OF STAY (LOS) IN PATIENTS UNDERGOING DIFFERENT CLEAN OR CLEAN-CONTAMINATED PROCEDURES
COST-BENEFIT ANALYSIS OF A STATE POISON CENTER
WHERE DOES THE GERMAN HEALTH CARE SYSTEM WANT TO GO TO?
THE IMPLICATIONS OF THE USE OF TUBE FEEDING IN THE UK SECONDARY HEALTH CARE SYSTEM
PAYMENTS FOR HIGH COST NEW TECHNOLOGY DRUGS AND BIOLOGICALS IN THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM
MANAGING TECHNOLOGICAL INNOVATION IN THE HEALTH CARE SECTOR
EVALUATION AND SELECTION OF MEDICAL HEALTH TECHNOLOGIES
THE EFFECTS OF GENETIC TESTING ON THE DEMAND FOR LIFE INSURANCE
SMOKING CESSATION
A MULTIDIMENSIONAL HEALTH CARE INTERVENTION APPRAISAL
USING PATIENT REPORTED OUTCOMES (PRO) DATA TO SEGMENT HEALTH CARE CONSUMERS AND UNCOVER THEIR RECEPTIVENESS TO PHARMACEUTICAL ADVERTISING
TREATMENT ADHERENCE WITH TNF-INHIBITORS AND METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A LARGE STATE MEDICAID PROGRAM
TOWARDS VALUING PREFERENCES FOR DISTRIBUTION OF HEALTH GAIN IN HIP AND KNEE DISEASE
EVALUATING THE IMPACT OF REIMBURSEMENT OF NON SELECTIVE COX2 INHIBITORS ON TOTAL DISPENSING OF SELECTED NSAID AND SELECTED DRUGS FOR ACID RELATED DISORDERS
ETANERCEPT VERSUS INFLIXIMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS
THE TOTAL COSTS OF TREATMENT WITH VALDECOXIB COMPARED TO GENERIC DICLOFENAC ARE SIMILAR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN GERMANY
ACUTE GOUTY ARTHRITIS
PHARMACOECONOMICS OF COX-2-SELECTIVE INHIBITORS VERSUS NON-SELECTIVE NSAIDS AND CONCOMITANT COUMARIN USE
AVERAGE DAILY DOSE AND COSTS OF REIMBURSED COX-2 INHIBITORS FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN NORWAY
PATTERNS OF USE, DOSING AND ECONOMIC IMPACT OF BIOLOGIC AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
CROSS-CULTURAL ADAPTATION AND VALIDATION OF KOREAN VERSION OF EQ-5D IN PATIENTS WITH RHEUMATIC DISEASES
IMPLEMENTATION STUDY OF A HEALTH EDUCATION AND EXERCISE PROGRAM FOR OSTEOARTHRITIS OF THE KNEE
ADAPTATION OF THE RAQOL FOR ESTONIA
UTILITY VALUATION FROM THE PATIENT PERSPECTIVE OF TREATMENT OUTCOMES IN OSTEOARTHRITIS
THE COST OF OSTEOPOROTIC FRACTURES IN FEMALES IN THE UK
THE BURDEN OF OSTEOPOROSIS IN EUROPE
AN ASSESSMENT OF THE ECONOMIC BURDEN OF BENZODIAZEPINE-ASSOCIATED HOSPITAL TREATED FALL INJURIES IN THE EUROPEAN UNION
COST-EFFECTIVENESS OF QUANTITATIVE ULTRASOUND AS A TECHNIQUE FOR SCREENING AND DIAGNOSING OSTEOPOROSIS AND SUBSEQUENTLY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES
COST-EFFECTIVENESS ANALYSIS OF DIFFERENT DRUG THERAPIES FOR OSTEOPOROSIS
AN ASSESSMENT OF THE UPDATED RESULTS FROM THE ARIMIDEX,TAMOXIFEN, ALONE OR IN COMBINATION (ATAC) TRIAL
BREAST CANCER PATIENTS' USE OF HEALTH CARE INFORMATION IN DECISION-MAKING AND IN COPING WITH ILLNESS
EXPERT PANEL DEPICTION OF CLINICAL PRACTICE IN THE TREATMENT OF BREAST CANCER PATIENTS IN GREECE
ANALYSIS ON COST DIFFERENCE BETWEEN DAILY FILGRASTIM AND ONCE PER CYCLE PEGFILGRASTIM FOR PROPHYLAXIS AGAINST CHEMOTHERAPY-INDUCED NEUTROPENIA IN FRANCE AND GERMANY
REPORT ON RETROSPECTIVE ANALYSIS OF HEALTH CARE COSTS OF BONE FRACTURES IN WOMEN WITH EARLY STAGE BREAST CANCER
HEALTH ECONOMIC EVALUATION OF A NEW CONTRAST PRODUCT FOR LIVER MRI IN COLORECTAL CANCER PATIENTS
ORAL VINORELBINE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER
PHARMACO-ECONOMIC ASSESSMENT OF CAPECITABINE ORAL CHEMOTHERAPY VERSUS FUFOL MAYO CLINIC CHEMOTHERAPY IN THE TREATMENT OF COLORECTAL CANCER
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)—OUTCOMES OF PROPHYLACTIC CARE AND COSTS IN GERMAN CANCER CENTERS
COSTS OF MANAGING TOXICITIES IN ADVANCED NON-SMALL CELL LUNG CANCER WITH PEMETREXED COMPARED WITH DOCETAXEL AS SECOND-LINE CHEMOTHERAPY
COMPARING THE PROVIDER TIME AND COSTS FOR RED BLOOD CELL TRANSFUSIONS IN ANAEMIA MANAGEMENT OF CANCER PATIENTS USING THE ACTIVITY-BASED COSTING (ABC) METHOD IN A FRENCH AND AUSTRIAN SETTING
BUDGET IMPACT ANALYSIS OF ANASTROZOLE AS ADJUVANT THERAPY IN THE TREATMENT OF EARLY BREAST CANCER IN THE UK
COST-EFFECTIVENESS OF MOHS'MICROGRAPHIC SURGERY VERSUS SURGICAL EXCISION FOR THE TREATMENT OF FACIAL BASAL CELL CARCINOMAS
COST IMPLICATIONS OF ORAL TREATMENT OF COLORECTAL CANCER IN GERMANY
COST ANALYSIS OF TREATMENT FOR ADVANCED OR RECURRENT GASTRIC CANCER IN JAPAN
HEAD AND NECK CANCER COSTS IN A FRENCH PRIVATE CENTRE
COST REDUCTION IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER USING ENDOSCOPIC ULTRASONOGRAPHY WITH FINE-NEEDLE ASPIRATION
THE COST OF GEMCITABINE/CISPLATIN COMPARED WITH FOUR OTHER NOVEL CHEMOTHERAPEUTIC AGENTS IN POLAND
COST ANALYSIS OF COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS OF PROSTATE CANCER
PEGFILGRASTIM IS PREFERRED TO FILGRASTIM IN CANCER PATIENTS ON MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT REGIMENS
COMPARISON OF PAIN OUTCOMES AND HRQL USING THE TREATMENT OUTCOMES IN PAIN SURVEY (TOPS) IN CANCER-RELATED PAIN
HEMOGLOBIN LEVELS ASSOCIATED WITH DIAGNOSIS OF ANEMIA
ROBABILITY OF INITIATING ERYTHROPOIETIC THERAPY
COST-EFFECTIVENESS OF HAEMOPHILIA TREATMENT
COST OF CARE AND QUALITY OF LIFE IN HEMOPHILIACS DEVELOPING INHIBITORS AGAINST PRODUCTS OF COAGULATION
HEALTH ECONOMIC ANALYSIS OF A SILVER CONTAINING HYDROACTIVATED FOAM DRESSING IN DELAYED HEALING LEG ULCERS
TREATMENT OF LEG ULCERS IN SWEDEN STILL DEMANDS LARGE RESOURCES IN SPITE OF IMPROVED MANAGEMENT—THE COST OF ILLNESS (COI) ESTIMATED FROM A PATIENT SURVEY AND PUBLISHED EPIDEMIOLOGICAL STUDIES
COST OF TREATMENT (COT) FOR VENOUS LEG ULCERS IN SWEDEN AND THE UK—ESTIMATES FROM CLINICAL EXPERT PANELS AND MODEL SIMULATIONS
COST-EFFECTIVENESS OF PATHOGEN INACTIVATION VIA THE INTERCEPT BLOOD SYSTEM FOR PLATELETS IN SPAIN
APPLICATION OF CONJOINT ANALYSIS TO ELICIT PREFERENCES IN HEMOPHILIA CARE
ASSESSING PATIENT PREFERENCES AND QUALITY-ADJUSTED LIFE YEARS (QALY) OF PROPHYLACTIC HAEMOPHILIA TREATMENT
DEVELOPMENT OF THE HAEMOPHILIA AGE-GROUP SPECIFIC QUALITY OF LIFE QUESTIONNAIRE
MORE PRECISE DOSING INCREMENTS OF HUMAN GROWTH HORMONE DELIVERY SYSTEMS LEAD TO COST SAVINGS IN THE UK SETTING
THE USE OF A CONDITION-SPECIFIC QUALITY OF LIFE MEASURE (QUALITY OF LIFE— ASSESSMENT FOR GROWTH HORMONE DEFICIENCY IN ADULTS) IN A GENERAL POPULATION
PHARMACEUTICAL MANAGEMENT OF NEWLY HIV+ DIAGNOSED PATIENTS
ASSOCIATION BETWEEN UNSUCCESSFUL INITIAL EMPIRIC ANTIBIOTIC THERAPY AND HEALTH CARE RESOURCE USE AMONG PATIENTS UNDERGOING SURGERY FOR COMMUNITY-ACQUIRED INTRA-ABDOMINAL INFECTIONS IN SPAIN
ASSOCIATION BETWEEN SKIN TATOOS AND HEPATITIS B OF 1/2000 PRIVATES AT ADISORN FORT HOSPITAL, THAIALND
CONSUMPTION OF ANTIBIOTICS IN EUROPE
REGIONAL ANTIBIOTIC PRESCRIBING GUIDELINE ADHERENCE RESULTS
INDICATORS OF ANTIBIOTIC USE IN PRIMARY HEALTH CARE OF REPUBLIC OF SRPSKA
AN ANALYSIS OF IN-VITRO UROPATHOGEN SENSITIVITY DATA TO UPDATE THE GUIDELINES FOR THE EMPIRIC TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN ADULT WOMEN IN A MANAGED CARE SETTING
PROSPECTIVE STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTIONS IN GERMAN CHILDREN YOUNGER THAN 3 YEARS (PRI.DE)—ECONOMIC IMPACT OF HOSPITALIZED CASES
COST-EFFECTIVENESS OF TWO DIFFERENT VACCINATION STRATEGIES FOR THE PREVENTION OF MENINGOCOCCAL C DISEASE IN PORTUGAL
A COST CONSEQUENCE ON CONCOMITANT DRUG USE DURING HCV THERAPY IN MANAGED CARE PATIENTS IN THE UNITED STATES
ABACAVIR HYPERSENSITIVITY
THE COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS INTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND
COST-EFFECTIVENESS OF VORICONAZOLE COMPARED WITH CONVENTIONAL AMPHOTERICIN B IN FIRST LINE TREATMENT OF INVASIVE ASPERGILLOSIS IN BELGIUM
POST-EXPOSURE INFLUENZA PROPHYLAXIS WITH OSELTAMIVIR
COST-EFFECTIVENESS ANALYSIS OF VORICONAZOLE VERSUS AMPHOTERICIN B IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN SPAIN
COST-EFFECTIVENESS ANALYSIS OF FUZEON ADDED TO OPTIMAL STANDARD THERAPY VS. OPTIMIZED BACKGROUND REGIMEN ALONE IN PATIENTS WITH HIV/AIDS
COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITAL'S PERSPECTIVE IN GERMANY—A PROSPECTIVE OBSERVATIONAL STUDY
PROJECTED CLINICAL BENEFITS AND COSTEFFECTIVENESS OF AN HPV 16/18 VACCINE
ECONOMIC IMPACT OF ANTIRETROVIRAL DRUG PRICE REDUCTIONS IN NINE LATIN AMERICAN COUNTRIES
THE IMPACT OF COST-EFFECTIVENESS OF COUNTRY SPECIFIC APPLICATION—THE CASE OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE SEPSIS
BUDGET IMPACT ANALYSIS OF UNIVERSAL VARICELLA VACCINATION IN GERMANY
MODELLING THE COST-EFFECTIVENESS OF THE VARICELLA VACCINE IN PORTUGAL
SPANISH HEALTH INTERVENTIONS FOR CHRONIC HEPATITIS B AND THEIR ASSOCIATED COSTS
THE COST-EFFECTIVENESS OF 23-VALENT PNEUMOCOCCAL VACCINE IN CATALONIA, SPAIN
COST-EFFECTIVENESS OF A PHARMACY-BASED SCREENING FOR CHLAMYDIA TRACHOMATIS
COST OF MANAGING CHRONIC HEPATITIS B IN THE UK
COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF THE USE OF ANTIVIRALS FOR THE TREATMENT OF INFLUENZA IN HEALTHY ADULTS
HOSPITAL MANAGEMENT OF PERTUSSIS IN GERMANY
REDUCING INFLUENZA SYMPTOMS BY 1.5 DAYSA PROSPECTIVE RANDOMIZED TRIAL USING THE CONTINGENT VALUATION METHOD TO ELICIT PREFERENCES FOR NEURAMINIDASE INHIBITORS
COSTS OF PULMONARY TUBERCULOSIS IN UKRAINE
COST-EFFECTIVENESS ANALYSIS OF ONCE-DAILY MODIFIED RELEASE CLARITHROMYCIN VERSUS CONVENTIONAL TWICE-DAILY GENERIC CLARITHROMYCIN FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS
THE POTENTIAL EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF A NEW COMBINATION VACCINE AGAINST MENINGOCOCCAL B AND C AND PNEUMOCOCCAL INFECTIONS IN THE NETHERLANDS
COST-EFFECTIVENESS OF DIFFERENT TREATMENT STRATEGIES WITH INTRAPARTUM ANTIBIOTIC PROPHYLAXIS TO PREVENT EARLY-ONSET GROUP B STREPTOCOCCAL DISEASE
COST-EFFECTIVENESS OF TWO SCREENING STRATEGIES FOR CHLAMYDIA TRACHOMATIS INFECTIONS IN FRANCE
MENINGOCOCCAL C VACCINATION OF CHILDREN AGED LESS THAN 1 YEAR
COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS AMONG PRETERM INFANTS IN POLAND
INTRODUCTION OF A NEW HEALTH TECHNOLOGY, POTENTIAL BEHAVIOURAL AND ORGANISATIONAL CHANGES AND POLICY IMPACT—ASSESSMENT OF NEW INFLUENZA TREATMENTS
COST-EFFECTIVENESS ANALYSIS OF PEGYLATED INTERFERONS COMBINED WITH RIBAVIRIN IN THE TREATMENT OF HEPATITIS C
DIRECT COST ANALYSIS OF HEPATITIS B INFECTION IN FRANCE
PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM HERPES LABIALIS WITH IN FRANCE—INSTANT STUDY
DEVELOPMENT OF THE HERPES OUTBREAK IMPACT QUESTIONNAIRE (HOIQ)
MEASURING TREATMENT-SPECIFIC ASPECTS OF HRQL IN PATIENTS SUFFERING FROM PRIMARY ANTIBODY DEFICIENCIES
CARE OF PARKINSON'S DISEASE PATIENTS IN EUROPEAN COUNTRIES; EUROPEAN COOPERATIVE NETWORK FOR RESEARCH, DIAGNOSIS AND, THERAPY OF PARKINSON'S DISEASE (EUROPA)
COST-EFFECTIVENESS OF ELETRIPTAN 40 MG COMPARED WITH STANDARD DOSES OF AVAILABLE TRIPTANS FOR ACUTE MIGRAINE ATTACKS IN SPAIN
A COST EFFECTIVENESS ANALYSIS OF ZOLMITRIPTAN NASAL SPRAY
COST-EFFECTIVENESS STUDY OF RIZATRIPTAN VS. USUAL CARE IN THE TREATMENT OF MIGRAINE IN CANADA
MANAGEMENT COSTS OF CHEST AND CNS-RELATED ADVERSE EVENTS OF TRIPTANS (SEROTONIN 5-HTIB/ID AGONISTS) IN SPAIN
INDIRECT COSTS DUE TO MIGRAINE IN THE UNITED STATES
A COST-EFFECTIVENESS ANALYSIS OF ELETRIPTAN 40 MG AND 80 MG VERSUS SUMATRIPTAN 50 MG AND 100 MG IN THE ACUTE TREATMENT OF MIGRAINE
ALZHEIMER'S DISEASE COST OF TREATMENT STUDY (ADCOT) IN THE UNITED KINGDOM
TIME SPENT AND COST ON INFORMAL CARE GIVING FOR PERSONS WITH ALZHEIMER IN SPAIN
COST EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATELY SEVERE AND SEVERE ALZHEIMER'S DISEASE IN SPAIN
IMPACT OF DEEP BRAIN STIMULATION (DBS) OF THE SUBTHALAMIC NUCLEUS (STN) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH CARE RESOURCE USE IN ADVANCED PARKINSONIAN PATIENTS
EARLY DECISION MAKING MODELLING IN PARKINSON'S DISEASE—THE CASE OF NEURAL TRANSPLANTATION IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
ECONOMIC EVALUATION OF DATSCAN IN THE DIAGNOSIS OF PARKINSONISM
SOCIO-ECONOMIC IMPACT OF EPILEPSY ON PARENTS
DO PEOPLE CONSIDER THE EFFECTS OF ILL-HEALTH ON INCOME AND LEISURE WHEN ANSWERING HEALTH-RELATED QUALITY-OF-LIFE QUESTIONS?
THE COSTS OF MULTIPLE SCLEROSIS—A CROSS-SECTIONAL PROSPECTIVE MULTI-CENTRE COST OF ILLNESS STUDY IN POLAND
RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORT® AND BOTOX® IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM—COST CONSIDERATIONS FOR THE REAL DOSE STUDY
COST-EFFECTIVENESS OF Z DRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) VERSUS BENZODIAZEPINES FOR THE SHORT—TERM MANAGEMENT OF INSOMNIA
RESOURCE UTILISATION AND COSTS OF PATIENTS WITH SPINAL CORD INJURY (SCI) AFTER INITIAL REHABILITATION
VALIDATION OF SINGAPOREAN ENGLISH AND CHINESE EQ-5D VERSIONS IN PATIENTS WITH PARKINSON'S DISEASE
PIRIBEDIL IMPROVES QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE IN RUSSIA
SOCIO-ECONOMIC IMPACT OF PARKINSONS DISEASE ON SPOUSES
INTERNATIONAL USE OF HEALTH STATUS QUESTIONNAIRES IN PARKINSON'S DISEASE
RIVASTIGMINE IS ASSOCIATED WITH SIGNIFICANTLY LESS CAREGIVER BURDEN THAN DONEPEZIL OR GALANTAMINE
DRUG PERSISTENCE PATTERNS SIMILAR FOR RIVASTIGMINE-TREATED PATIENTS AND DONEPEZIL-TREATED PATIENTS
STANDARD GAMBLE TECHNIQUE—A TOOL TO ASSESS QUALITY OF LIFE IN PATIENTS WITH EPILEPSY
FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS (FAMS)
TOPIRAMATE FOR THE TREATMENT OF PERIPHERAL DIABETIC NEUROPATHY
TOPIRAMATE IS EFFECTIVE IN PATIENTS WITH PERIPHERAL DIABETIC NEUROPATHY FOR WHOM OTHER ANTICONVULSANTS HAVE FAILED
A UK MULTI-CENTRE TRIAL-BASED COST-UTILITY ANALYSIS OF SURGICAL STABILISATION OF THE SPINE VERSUS INTENSIVE REHABILITATION FOR TREATMENT OF CHRONIC LOW BACK PAIN PATIENTS
EPIDEMIOLOGY, CO-MORBIDITY,AND IMPACT ON HEALTH-RELATED QUALITY OF LIFE OF SELF-REPORTED HEADACHE AND MUSCULOSKELETAL PAIN—A GENDER PERSPECTIVE
ASSESSING PATIENT SATISFACTION WITH PHARMACOLOGICAL PAIN TREATMENT IN AMBULATORY PRIMARY CARE PATIENTS
CRITICAL PATHWAY STATUS
THE WILLINGNESS-TO-PAY APPROACH IN THE COST-BENEFIT ANALYSIS
SUSTAINED-RELEASE TRAMADOL IN CHRONIC PAIN TREATMENT
CHRONIC PAIN PATIENTS' SATISFACTION AND QUALITY OF LIFE WITH TRANSDERMAL ANALGESIC MEDICATION
EPIDEMIOLOGY OF NASAL POLYPS AND ITS RELATIONSHIP TO ASTHMA
HELIOX IN THE TREATMENT OF STATUS ASTHMATICUS IN THE ICU
LOSSES IN PRODUCTIVITY DUE TO ASTHMA
COST-UTILITY OF BECLOMETHASONE-EXTRAFINE (BDP-EF) IN PATIENTS WITH MODERATE AND SEVERE ASTHMA
COST-EFFECTIVENESS OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION PRODUCT 50/100 MCG TWICE DAILYAND BUDESONIDE 400 MCG TWICE DAILY IN THE TREATMENTOF ADULTS WITH ASTHMA IN CHINA
COST OF ASTHMA EXACERBATION IN THE HOSPITAL SETTING IN SPAIN
A CROSS-SECTIONAL, OBSERVATIONAL STUDY TO ESTABLISH THE RESOURCES AND COSTS ASSOCIATED WITH CONTROLLED AND POORLY CONTROLLED MODERATE TO SEVERE ASTHMA PATIENTS IN THE UK
THE COST-EFFECTIVENESS OF DIFFERENT INHALED COMBINATION THERAPIES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ASTHMA—A MODELING STUDY FROM HEALTH CARE PAYER PERSPECTIVE IN POLAND
INPATIENT MANAGEMENT OF ASTHMA IN CHILDREN AND ADOLESCENTS
A RANDOMIZED STUDY COMPARING THREE HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN ASTHMATIC PATIENTS
THE VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR PATIENTS WITH ASTHMA (WPAI-ASTHMA)
AST-PQ16
COSTS OF COPD IN GERMANY—RESULTS OF A COST-OF ILLNESS STUDY
COST OFFSETS FROM PRESCRIPTION COVERAGE OF AGED PERSONS WITH COPD
DO RESPIRATORY DRUGS REDUCE HOSPITAL ADMISSIONS? AN ECOLOGICAL STUDY CARRIED OUT IN MODENA, ITALY, TO INVESTIGATE DISTRICTS' VARIABILITY
COST-EFFECTIVENESS OF BUPROPION SR IN THE TREATMENT OF TOBACCO DEPENDENCE
ESTIMATING HOSPITAL BURDEN DUE TO PNEUMONIA, ASPIRATION, AND ACUTE LUNG FAILURE
ANALYSIS OF LONGITUDINAL CHANGES IN QUALITY OF LIFE BEFORE AND AFTER LUNG TRANSPLANTATION USING A MULTI-LEVEL MODEL
DERMATOLOGICAL DISEASES AND PODIATRIC DISORDERS IN THE FEET OF THE ELDERLY POPULATION
EFFECTIVITY AND SAFETY OF TACALCITOL IN PSORIASIS VULGARIS IN SPANISH PATIENTS
MANAGEMENT AND SOCIO ECONOMIC IMPACT OF ATOPIC DERMATITIS (AD) IN FRANCE
ECONOMIC EVALUATION OF TACROLIMUS OINTMENT VERSUS CURRENT CARE IN MODERATE TO SEVERE ATOPIC DERMATITIS
THE COST-UTILITY OF CALCIPOTRIOL/BETHAMETHASONE (DOVOBET) OINTMENT IN THE TREATMENT OF PSORIASIS VULGARIS IN THE UNITED KINGDOM
CHILDREN'S ATOPIC DERMATITIS
TREATMENT OF PSORIASIS WITH CONVENTIONAL SYSTEMIC AGENTS IS ASSOCIATED WITH HIGH MEDICAL COSTS AND FREQUENT TREATMENT FAILURE
COST-OF-ILLNESS STUDY IN PATIENTS SUFFERING FROM CHRONIC PLAQUE PSORIASIS IN GERMANY
PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM INFLAMMATORY DERMATITIS (PSORIASIS, ECZEMA, ATOPIC DERMATITIS AND URTICARIA) IN FRANCE–INSTANT STUDY
THE USE OF DISCRETE CHOICE ANALYSIS TO ASSIST WITH THE INTERPRETATION OF QUALITY OF LIFE SCORES
THE WILLINGNESS-TO-PAY FOR PSORIASIS TREATMENT IN DENMARK
QUALITY-OF-LIFE IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY
COSTEFFECTIVENESS OF ALEFACEPT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
QUALITY OF LIFE IN PATIENTS SUFFERING FROM PSORIASIS VULGARIS IN GERMANY A NON INTERVENTIONAL SURVEY
DURATION OF PSORIASIS AND QUALITY OF LIFE
PSORIASIS
PSORIASIS AND QUALITY OF LIFE SPANISH RESULTS
PSORIASIS
DERMATOSIS AND DEPRESSIVE SYMPTOMATOLOGY
QUALITY OF LIFE AND PSORIASIS. IMPACT OF TACALCITOL TREATMENT IN SPANISH POPULATION
PROPERLY ADDRESSING TIME-DEPENDENCE WHEN ANALYZING THE IMPACT OF COMPLIANCE WITH MEDICATION IN CHRONIC ILLNESSES
DISABILITY IN STROKE OUTCOMES RESEARCH
OUTCOMES OF AN INTERVENTION TO IMPROVE HOSPITAL ANTIBIOTIC PRESCRIBING
DIFFERENCES IN PATIENT BURDEN BETWEEN ENDOANAL MRI, DEFECOGRAPHY AND ANORECTAL FUNCTIONAL TESTING FOR PATIENTS WITH FAECAL INCONTINENCE
A METHOD FOR IDENTIFICATION OF FRONTIER PRACTICE IN DIABETES CARE
DEVELOPMENT OF A WEB-BASED SURVEY TO DETERMINE PRACTICE PATTERNS FOR TREATMENT OF ADVANCED STAGE BREAST CANCER IN FIVE EUROPEAN COUNTRIES
DATA ACQUISITION AND INTEGRATION FOR ANTIBIOTIC TREATMENT REPORTING
PREDICTORS OF ANTIBIOTIC PRESCRIBING FOR UPPER RESPIRATORY INFECTIONS IN AN AMBULATORY POPULATION
OPTIMIZATION OF AIDS PILOT CLINICAL TRIAL USING LEAMSIM
GENETIC TESTING, PREDICTIVE GENETIC TESTING FOR HEREDITARY CANCER
SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OFCARE, OFFER AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLE THE DERIVATION OF PRACTICE-WIDE TREATMENT GUIDELINES
COST SOURCE AND PERSPECTIVE IN ECONOMIC OUTCOMES STUDIES
WITHDRAWN
WILLINGNESS TO PAY, WILLINGNESS TO WAIT, AND SUPER QALYS
THE INTERNATIONAL COSTING SOURCES DATABASE
UNCERTAINTY AND VALUE OF INFORMATION IN RAPID ECONOMIC EVALUATIONS
PROTOCOL FOR MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS
INDIRECT COSTS OF A LARGE-SCALE IMMUNIZATION PROGRAM-WHEN COSTS EXCEED SAVINGS
THE COST-EFFECTIVENESS OF TREATMENT FOR TYPE 1 DIABETES
THE COST-EFFECTIVENESS OF SCREENING PROGRAMS USING SINGLE AND MULTIPLE BIRTH COHORT SIMULATIONS
LIFE EXPECTANCY AND THE DISCOUNTING OF HEALTH OUTCOMES
EPIDEMIOLOGY AND PHARMAECONOMY OF COPD ACROSS EUROPE
IDENTIFICATION OF UNIT COSTS IN RHEUMATOID ARTHRITIS-RESEARCH APPROACH AND RESULTS
FIRST EXPERIENCES WITH THE CONDUCTION OF RAPID HEALTH ECONOMIC HEALTH TECHNOLOGY ASSESSMENTS
THE TIME INCONSISTENCY OF DECISIONS IN PHARMACOECONOMIC SEQUENTIAL DECISION PROBLEMS
COST-ASSESSMENT RE-CONSIDERED
CHALLENGES FOR MODEL-BASED ECONOMIC EVALUATIONS OF GLAUCOMA AND OCULAR HYPERTENSION TREATMENTS
A MULTI-OUTCOME DECISION MODEL FOR PARKINSON'S DISEASE
MODELLING OF PREVALENCE, COSTS AND OUTCOME OF ACID-RELATED DISORDERS USING CLAIMS DATA
DECISION-ANALYTIC MODELING IN PARKINSON'S DISEASE
ENSURING A STANDARD USER INTERFACE FOR MODELS
THE USE OF A SEMI-MARKOV PROCESS MODEL IN COST-EFFECTIVENESS MODELING
ANALYTIC CHOICES IN ECONOMIC MODELS OF TREATMENTS FOR RHEUMATOID ARTHRITIS
A METHODOLOGICAL APPROACH TO ASSESS COST DUE TO DYING IN THE CONTEXT OF DECISION ANALYTIC MODELLING
ARE ISPOR SHORT COURSES A COSTEFFECTIVE WAY OF EDUCATING PARTICIPANTS AND ENHANCING MEETING ATTENDANCE?
RECOMMENDATIONS TO THE EUROPEAN REGULATORS FOR THE CROSS-CULTURAL ADAPTATION OF PRO MEASURES
WORST AND BEST EYE VISUAL ACUITY CONSEQUENCES ON VISION-RELATED QUALITY OF LIFE IN PATIENTS SUFFERING FROM AGE RELATED MACULAR DEGENERATION
DESCRIPTION OF THE PRINCIPLES OF GOOD PRACTICE FOR TRANSLATION AND CULTURAL ADAPTATION OF PRO MEASURES
UTILISATION OF THE FOCUS GROUP TECHNIQUE IN THE DEVELOPMENT OF QUALITY OF LIFE QUESTIONNAIRES
THE NATURE OF THE QUALITY-ADJUSTED LIFE YEAR (QALY) CALCULATION
LINGUISTIC VALIDATION OF THE QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE (Q-LES-Q) IN 24 LANGUAGES
BENEFITS OF TRANSLATABILITY ASSESSMENT TO ENHANCE THE COHERENCE OF DATA IN INTERNATIONAL STUDIES-THE IQOD EXPERIENCE
ADVANCING RISK ADJUSTMENT FOR SCHIZOPHRENIA
OUTCOMES RESEARCH AND PHASE 1–2 PHARMACEUTICAL RISK ASSESSMENT
PROCESS UTILITY DERIVED FROM PROVIDING INFORMAL CARE
CALCULATING UTILITY VALUES FROM SF-36
RELATIVE WEIGHTS ASSIGNED TO DRUGS AND BIOLOGICALS